Preliminary Analysis of Patients With Progressive Renal Cell Carcinoma Vaccinated With CA9-peptide–Pulsed Mature Dendritic Cells
Authors:
- Dorien M. TiemessenDTDorien M. Tiemessen
- Jeannette C. Oosterwijk-WakkaJOJeannette C. Oosterwijk-Wakka
- Maureen C. W. VöllerMVMaureen C. W. Völler
- Kim De WeijerKWKim De Weijer
- Peter F. A. MuldersPMPeter F. A. Mulders
- Egbert OosterwijkEOEgbert Oosterwijk
- 1 January 2007
- journal article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 30 (1) , 116-122
Abstract
Carbonic anhydrase-IXG250/MN (CA9) is a renal cell carcinoma (RCC)-associated antigen ubiquitously expressed in the clear-cell subtype of RCC. Two CA9-derived peptides have been identified defining a cytotoxic T-lymphocyte epitope and human leukocyte antigen (HLA)-DR epitope, able to induce T-cell responses in vitro. A phase I clinical trial was performed with CA9-peptide–loaded dendritic cells (DCs) in patients with progressive, cytokine-refractory metastatic RCC to assess the safety, toxicity, and induction of CA9-specific immunity. Patients with objective progressive metastatic RCC received 5 vaccinations of mature DCs pulsed with the CA9-derived peptides and keyhole limpet hemocyanine (KLH). Peripheral blood was collected at regular intervals, delayed-type hypersensitivity (DTH) was tested at baseline and after the last vaccination, and skin biopsies of positive DTH sites were collected for immunomonitoring purposes. Patients were also monitored for clinical responses. No significant toxicity was observed. All patients developed humoral responses against KLH, and demonstrated DTH conversion. Evaluation of biopsy material suggested an increased influx of T-helper cells. In none of the immunomonitoring assays was evidence for the induction of CA9-peptide–specific immunity observed. No clinical responses were observed. The vaccination of DCs pulsed with KLH and 2 CA9-derived peptides was well tolerated. The lack of induction of CA9-peptide–specific immune responses indicates that this particular vaccine regimen is poor in inducing CA9-peptide–specific immune responses.Keywords
This publication has 10 references indexed in Scilit:
- Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical OutcomeJournal of Clinical Oncology, 2005
- Novel treatment strategies in clear-cell metastatic renal cell carcinomaAnti-Cancer Drugs, 2005
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Immunotherapy for Renal Cell CarcinomaEuropean Urology, 2003
- Vaccination of Patients With Metastatic Renal Cell Carcinoma With Autologous Dendritic Cells Pulsed With Autologous Tumor Antigens in Combination With Interleukin-2: A Phase 1 StudyJournal of Immunotherapy, 2002
- Renal cell carcinoma–associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen‐dr molecules to CD4+ T lymphocytesInternational Journal of Cancer, 2002
- Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250International Journal of Cancer, 2000
- Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidneyInternational Journal of Cancer, 1986